首页> 外国专利> Method for differential quantification of naturally processed HLA-restricted peptides that are intended for the development of cancer immunotherapies and against autoimmune and infectious diseases

Method for differential quantification of naturally processed HLA-restricted peptides that are intended for the development of cancer immunotherapies and against autoimmune and infectious diseases

机译:用于开发用于癌症免疫疗法以及针对自身免疫和传染病的天然加工的HLA限制肽的差异定量方法

摘要

Method for the identification and quantification without labeling of at least one MHC peptide ligand in one or more primary tissue samples from at least one mammal, wherein said method comprises: a) Isolation of at least one MHC peptide ligand a starting from at least a first healthy tissue sample and a second diseased tissue sample corresponding to said primary diseased tissue, b) Carrying out an analysis by HPLC-MS of said MHC peptide ligands in order to generate a signal of such peptides c) Determination of the signal area of the precursor ion for each of said MHC peptide ligand signals d) identification of the sequences of each of the said MHC peptide ligands, by grouping the fragmentation spectra and / or database search e) Determination of an average amount of the MHC peptide ligand by grouping the areas obtained in different series of analyzes is repeated and the normalization of said areas within each of the analysis series, in order to create an average value for each sample f) Determination of relative amounts of the MHC peptide ligand that are comparable between the samples, which comprises f1) Assignment of the MHC peptide ligand to a subset of allele-specific sequences for comparison between different samples by identifying at least one MHC allele to which the MHC peptide ligand is predicted to bind, and f2) Normalization between different samples by allele specific subgroups to account for different sample sizes and / or MHC expression levels; and f3) Execution of a quality control of the data based on the reproducibility of the peptide in each sample g) Determination of the over-presentation of the MHC peptide ligand by calculating a presentation profile and / or a presentation score corresponding to the MHC peptide ligand from said diseased tissue sample and from said healthy tissue sample based on said average and relative amounts of MHC peptide ligand, and h) Unlabeled quantification of MHC peptide ligand.
机译:在不标记至少一种哺乳动物的一个或多个原始组织样品中至少一种MHC肽配体的情况下进行鉴定和定量的方法,其中所述方法包括:a)从至少第一种方法中分离出至少一种MHC肽配体a健康组织样品和对应于所述主要病变组织的第二个病变组织样品,b)通过HPLC-MS对所述MHC肽配体进行分析,以产生此类肽的信号,c)确定前体的信号区每个MHC肽配体信号的离子d)通过对碎片谱进行分组和/或数据库搜索来鉴定每个所述MHC肽配体的序列e)通过对区域进行分组来确定MHC肽配体的平均数量重复在不同系列的分析中获得的结果,并对每个分析系列中的所述区域进行归一化,以创建每个样本f的平均值)确定样品之间可比较的MHC肽配体的相对量,包括f1)通过鉴定至少一个MHC等位基因,将MHC肽配体分配给等位基因特异性序列的一个子集,以便在不同样品之间进行比较预测MHC肽配体将结合,并且f2)通过等位基因特异性亚组在不同样品之间归一化以说明不同的样品大小和/或MHC表达水平; f3)基于每个样品中肽的可重复性对数据进行质量控制g)通过计算呈递谱和/或与MHC肽相对应的呈记分数,确定MHC肽配体的超表达基于所述MHC肽配体的平均和相对量,从所述患病组织样品和所述健康组织样品中获得的配体,以及h)MHC肽配体的未标记定量。

著录项

  • 公开/公告号ES2658268T3

    专利类型

  • 公开/公告日2018-03-09

    原文格式PDF

  • 申请/专利权人 IMMATICS BIOTECHNOLOGIES GMBH;

    申请/专利号ES20110714563T

  • 发明设计人 WEINSCHENK TONI;FRITSCHE JENS;

    申请日2011-04-15

  • 分类号G01N33/68;

  • 国家 ES

  • 入库时间 2022-08-21 12:48:40

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号